XML 44 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Management determined that the Company is managed as one operating segment, and thus reports as a single reportable segment. This operating segment is focused on the development and global commercialization of clinical laboratory services allowing healthcare providers and patients to make individualized treatment decisions. Management assessed the financial information routinely reviewed by the Company's Chief Operating Decision Maker (“CODM”), its President and Chief Executive Officer, to monitor the Company's operating performance and support decisions regarding allocation of resources to its operations, and determined that performance is continuously monitored at the consolidated level. The measure of segment profit or loss used by the CODM in assessing performance and deciding how to allocate resources is based on net loss, as reported on the consolidated statement of operations. The measure of segment assets provided to and reviewed by the CODM is reported on the consolidated balance sheet as total assets, and long-lived assets located in countries outside the U.S. are not significant. The CODM uses consolidated net loss to monitor budget versus actual results on a monthly basis to timely identify deviations from expected results, which is used in assessing performance and deciding where to reinvest profits and allocate resources predominantly in the annual budget and forecasting process.
Significant segment expenses are presented in the Company's consolidated statements of operations. Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company's consolidated statements of operations, are presented below, along with total revenue from customers by geographic region.
Year Ended December 31,
(In thousands)202420232022
Revenue:
United States$2,569,775 $2,346,489 $1,966,541 
Outside of United States189,092 153,277 117,738 
Total revenues (1)2,758,867 2,499,766 2,084,279 
Less:
Cost of sales:
Production costs467,347 393,367 329,492 
Personnel expenses197,338 182,015 160,136 
Intangible asset amortization84,068 83,316 86,967 
Facility and support services (2)68,535 54,417 63,608 
Stock-based compensation20,518 20,761 19,218 
Other cost of sales
2,344 3,688 1,940 
Research and development expenses:
Personnel expenses182,190 180,281 143,259 
Direct research and development costs110,054 129,691 158,731 
Facility and support services (2)56,184 64,088 45,512 
Stock-based compensation39,684 41,242 33,825 
Other research and development (3)
28,900 3,371 8,179 
Professional & legal10,906 7,209 3,912 
Intangible asset amortization3,292 1,045 773 
Sales and marketing expenses:
Personnel expenses500,286 471,613 494,116 
Direct marketing costs212,838 183,720 238,111 
Professional & legal70,399 49,739 54,698 
Stock-based compensation68,236 73,016 69,267 
Other sales and marketing (3)
19,287 24,348 13,432 
Facility and support services (2)15,385 17,675 50,419 
Intangible asset amortization7,694 7,694 9,601 
General and administrative expenses:
Personnel expenses346,432 336,865 341,595 
Facility and support services (2)184,984 181,425 134,954 
Professional & legal125,608 166,760 110,039 
Stock-based compensation86,447 96,293 84,513 
Other general and administrative (3)
38,250 18,841 (7,827)
Intangible asset amortization104 104 107 
Other:
Impairment of long-lived and indefinite-lived assets869,460 621 15,969 
Other segment items (4)
(21,742)(91,693)52,303 
Income tax expense (benefit)(7,304)2,403 (9,064)
Segment and consolidated net loss$(1,028,857)$(204,149)$(623,506)
_______________________________
(1) Product revenues are attributed to countries based on ship-to location. Refer to Note 2 for the Company’s disaggregated revenue disclosures.
(2)     Facilities and support services is inclusive of depreciation expense. Refer to the consolidated statements of cash flows for presentation of total depreciation expense.
(3) Other research and development primarily includes a $25.8 million for a license agreement termination for the year ended December 31, 2024. Other sales and marketing primarily includes miscellaneous customer-oriented support activities. Other general and administrative primarily includes changes in fair value to outstanding contingent consideration liabilities, foreign currency gains and losses, corporate liability insurance, and other miscellaneous charges.
(4) Inclusive of other operating income (loss), investment income (loss), net, and interest expense as presented in the consolidated statement of operations.